NO953286L - Benstimulerende faktor - Google Patents

Benstimulerende faktor

Info

Publication number
NO953286L
NO953286L NO953286A NO953286A NO953286L NO 953286 L NO953286 L NO 953286L NO 953286 A NO953286 A NO 953286A NO 953286 A NO953286 A NO 953286A NO 953286 L NO953286 L NO 953286L
Authority
NO
Norway
Prior art keywords
gly
polypeptide
lys
ala
pro
Prior art date
Application number
NO953286A
Other languages
English (en)
Other versions
NO953286D0 (no
Inventor
Cherk Shing Tam
Original Assignee
Osteopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteopharm Ltd filed Critical Osteopharm Ltd
Publication of NO953286D0 publication Critical patent/NO953286D0/no
Publication of NO953286L publication Critical patent/NO953286L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

En polypeptidsubstans som isoleres fra rotteserum og som, ved administrering til rotter som er ute av stand til å produsere PTH (paratyroidectomiserte rotter), frembringer en økning i den observerte hastighet for benmineralapposisjon. Stoffet har blitt isolert i to former, et første større polypeptid med en molekylvekt på ca. det dobbelte av et andre mindre polypeptid. De første elleve aminosyrer fra det mindre polypeptids sekvens er bestemt å være Gly Pro Gly Gly Ala Gly Glu Thr Lys Pro Ile. De første syv aminosyrer fra det større polypeptid er bestemt å være Gly Pro Gly Gly Ala Gly Glu. Det større polypeptid kan være dimeren av det mindre polypeptid. En nukleinsyreprobe som er basert på rottepeptidets aminosyresekvens ble benyttet for å gjennomsøke et fetalt humant cDNA-leverbibliotek. Et polypeptid ble således kjemisk syntetisert ifølge sekvensen Gly Ile Gly Lys Arg Thr Asn Glu His Thr Ala Asp Cys Lys Ile Lys Pro Asn Thr Leu His Lys Lys Ala Ala Glu Thr Leu Met Val Leu Asp Gin Asn Gin Pro. Benapposisjonshastigheten i rotter øker på en doseavhengig måte ved administrering av denne kjemisk syntetiserte forbindelse.
NO953286A 1993-03-12 1995-08-22 Benstimulerende faktor NO953286L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3138693A 1993-03-12 1993-03-12
US12021793A 1993-09-13 1993-09-13
PCT/CA1994/000144 WO1994020615A1 (en) 1993-03-12 1994-03-14 Bone stimulating factor

Publications (2)

Publication Number Publication Date
NO953286D0 NO953286D0 (no) 1995-08-22
NO953286L true NO953286L (no) 1995-10-25

Family

ID=26707172

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953286A NO953286L (no) 1993-03-12 1995-08-22 Benstimulerende faktor

Country Status (19)

Country Link
EP (1) EP0688360B1 (no)
JP (1) JP3733381B2 (no)
KR (1) KR960701201A (no)
CN (1) CN1119457A (no)
AT (1) ATE208818T1 (no)
AU (1) AU678441B2 (no)
BR (1) BR9406447A (no)
CA (1) CA2157901A1 (no)
CZ (1) CZ234295A3 (no)
DE (1) DE69429082T2 (no)
ES (1) ES2168295T3 (no)
FI (1) FI954252A (no)
HU (1) HUT73297A (no)
IL (1) IL108947A0 (no)
NO (1) NO953286L (no)
NZ (1) NZ262352A (no)
PL (1) PL182236B1 (no)
TW (1) TW385314B (no)
WO (1) WO1994020615A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786327A (en) 1993-03-12 1998-07-28 Gensci Regeneration Sciences Inc. Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same
US5880094A (en) * 1995-06-07 1999-03-09 Osteopharm Limited Polypeptides that stimulate bone growth
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
US6352973B1 (en) 1995-06-07 2002-03-05 Osteopharm Inc. Bone stimulating factor
US6693081B2 (en) * 1995-09-26 2004-02-17 Osteopharm Inc. Bone stimulating factor
DE69838768T2 (de) 1997-09-19 2008-10-30 Metabolix, Inc., Cambridge Biologische Systeme zur Herstellung von Polyhydroxyalkanoat-Polymeren die 4-Hy droxysäure enthalten
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
AU5379200A (en) * 1999-06-02 2000-12-28 Osteopharm Inc. Bone stimulating factor
DE60026150T2 (de) 1999-08-30 2006-11-16 Interleukin Genetics, Inc., Waltham Diagnostika und therapeutika für osteoporose
US6815421B1 (en) 2001-03-22 2004-11-09 Osteopharm Inc. Polypeptides for use in ameliorating effects of aging in mammals
CA2534365A1 (en) 2003-08-08 2005-02-17 Interleukin Genetics, Inc. Diagnostic and therapeutics for osteoporosis
ATE475670T1 (de) * 2006-12-21 2010-08-15 Numat As Konsensus-peptid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0128041A3 (en) * 1983-06-06 1986-12-03 David Jeston Baylink Polypeptides exhibiting skeletal growth factor activity
CA2020729A1 (en) * 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein

Also Published As

Publication number Publication date
KR960701201A (ko) 1996-02-24
JPH08508158A (ja) 1996-09-03
ES2168295T3 (es) 2002-06-16
HUT73297A (en) 1996-07-29
CZ234295A3 (en) 1996-04-17
PL310617A1 (en) 1995-12-27
EP0688360B1 (en) 2001-11-14
AU6179794A (en) 1994-09-26
DE69429082D1 (de) 2001-12-20
TW385314B (en) 2000-03-21
FI954252A0 (fi) 1995-09-11
JP3733381B2 (ja) 2006-01-11
WO1994020615A1 (en) 1994-09-15
FI954252A (fi) 1995-09-11
BR9406447A (pt) 1996-02-13
CA2157901A1 (en) 1994-09-15
ATE208818T1 (de) 2001-11-15
EP0688360A1 (en) 1995-12-27
NO953286D0 (no) 1995-08-22
NZ262352A (en) 1997-10-24
IL108947A0 (en) 1994-06-24
CN1119457A (zh) 1996-03-27
DE69429082T2 (de) 2002-07-25
PL182236B1 (pl) 2001-11-30
AU678441B2 (en) 1997-05-29
HU9502659D0 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
Gregory et al. The primary structure of human urogastrone
NO953286L (no) Benstimulerende faktor
EP1053255A4 (en) THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS, AND USES THEREOF
EP1175909A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
IE850436L (en) Peptides
SE8007763L (sv) Sett att framstella en polypeptid
DE3486154D1 (de) Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung.
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
ES466385A1 (es) Un procedimiento para la obtencion de un preparado de seroalbumina.
ATE386118T1 (de) Cnp-gen und vorläuferprotein aus schwein
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
RU93045577A (ru) Слитные полипептиды
Gelher et al. The sequence of an atriopeptigen: a precursor of the bioactive atrial peptides
US5814610A (en) Osteogenic growth oligopeptides and pharmaceutical compositions containing them
EP0182627A3 (en) Basic v1-vasopressin antagonists
JPH01131197A (ja) Ａｎｆ活性を有するペプチド類
CA2163212A1 (en) Therapeutic compounds
FERRARA et al. β‐Endorphin: Interaction of synthetic analogs having different chain lengths with morphine and enkephalin receptors in rat brain membranes
FR2691153B1 (fr) Dodecapeptides monomere et dimere, utilisation en tant qu'agents anti-megacaryocytaires.
Monet et al. In vitro relative biological activities of (1--34) N-terminal synthetic fragments of human parathyroid hormone in the human renal cortical adenylate cyclase assay
Ting et al. Effect of changing the COOH-terminal amide group present in the hydrophilic cluster of oxytocin to dimethylamide
JP2796835B2 (ja) ヒトカルパスタチン様ポリペプチド
Ganeshan et al. Recognition of neuropeptides FMRFamide and LPLRFamide by chicken cerebellum avian pancreatic polypeptide binding sites
JPH07278191A (ja) 新規ペプチドもしくは蛋白質及びそれを探索する方法
TH35998A (th) Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application